Latest News

Phase 3 LIBerate data showed sustained LDL-C reductions of 60% or more in high-risk patients and 50% or more in HeFH, with once-monthly self-administration.

Primary care physician Kevin Hatfield, MD, discusses how the switch can increase patient touchpoints, free cognitive burden, and strengthen long-term engagement between patients and PCPs.

Moving patients from considering screening to completing it remains the central challenge in colorectal cancer prevention, Fendrick explained to Patient Care.

Zasocitinib showed significant efficacy in treating moderate-to-severe plaque psoriasis, outperforming placebo and apremilast in pivotal phase 3 trials.

The phase 3 REDFINE program showed mean weight loss of 20% at 68 weeks, supporting the dual-mechanism approach that combines semaglutide with cagrilintide.

This is a summary of the multisystem effects of hidradenitis suppurativa followed by practical tips for primary care in recognizing and managing the chronic skin condition.

Your daily dose of the clinical news you may have missed.